- Home
- BFRI
BFRI
Biofrontera Inc.
as 09-04-2025 4:00pm EST
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 7.9M | IPO Year: | 2021 |
| Target Price: | $2.75 | AVG Volume (30 days): | 347.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.22 | Next Earning Date: | 08-13-2025 |
| Revenue: | $39,188,000 | Revenue Growth: | 11.20% |
| Revenue Growth (this year): | 11.07% | Revenue Growth (next year): | 11.20% |
Latest Biofrontera Inc. News
BFRI Breaking Stock News: Dive into BFRI Ticker-Specific Updates for Smart Investing
MT Newswires
3 months ago
Biofrontera Inc. Confirms Talks on Merger, Licensing Changes with Biofrontera AG
GlobeNewswire
3 months ago
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
GlobeNewswire
3 months ago
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
GuruFocus.com
4 months ago
Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...
Thomson Reuters StreetEvents
4 months ago
Q1 2025 Biofrontera Inc Earnings Call
GlobeNewswire
4 months ago
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
4 months ago
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
ACCESS Newswire
4 months ago
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025
Compare BFRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BFRI Biofrontera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.